WO2022153996A1 - 間葉系幹細胞、抗炎症剤及び神経疾患治療剤 - Google Patents
間葉系幹細胞、抗炎症剤及び神経疾患治療剤 Download PDFInfo
- Publication number
- WO2022153996A1 WO2022153996A1 PCT/JP2022/000658 JP2022000658W WO2022153996A1 WO 2022153996 A1 WO2022153996 A1 WO 2022153996A1 JP 2022000658 W JP2022000658 W JP 2022000658W WO 2022153996 A1 WO2022153996 A1 WO 2022153996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mesenchymal stem
- stem cells
- cells
- sirt1
- gene
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 180
- 208000012902 Nervous system disease Diseases 0.000 title claims abstract description 30
- 208000025966 Neurological disease Diseases 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 26
- 239000002260 anti-inflammatory agent Substances 0.000 title claims abstract description 23
- 229940121363 anti-inflammatory agent Drugs 0.000 title claims abstract description 23
- 108010041191 Sirtuin 1 Proteins 0.000 claims abstract description 119
- 102000000344 Sirtuin 1 Human genes 0.000 claims abstract description 97
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract description 3
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract description 3
- 230000014509 gene expression Effects 0.000 claims description 85
- 210000003954 umbilical cord Anatomy 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 abstract description 108
- 108090000623 proteins and genes Proteins 0.000 description 52
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 37
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 37
- 238000000034 method Methods 0.000 description 37
- 102000004169 proteins and genes Human genes 0.000 description 28
- 239000002158 endotoxin Substances 0.000 description 24
- 229920006008 lipopolysaccharide Polymers 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 238000003501 co-culture Methods 0.000 description 21
- 108020004999 messenger RNA Proteins 0.000 description 21
- 238000012258 culturing Methods 0.000 description 19
- 241000282412 Homo Species 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- 210000000577 adipose tissue Anatomy 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 14
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 13
- 239000002609 medium Substances 0.000 description 13
- 101150035467 BDNF gene Proteins 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 210000001185 bone marrow Anatomy 0.000 description 10
- 238000010586 diagram Methods 0.000 description 9
- 238000004520 electroporation Methods 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 241000282693 Cercopithecidae Species 0.000 description 8
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 8
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 102100031418 EF-hand domain-containing protein D2 Human genes 0.000 description 7
- 102100020760 Ferritin heavy chain Human genes 0.000 description 7
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 101001002987 Homo sapiens Ferritin heavy chain Proteins 0.000 description 7
- 101000986379 Homo sapiens High mobility group protein HMGI-C Proteins 0.000 description 7
- 102000018546 Paxillin Human genes 0.000 description 7
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 7
- 102100020814 Sequestosome-1 Human genes 0.000 description 7
- 102100027287 Serpin H1 Human genes 0.000 description 7
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 7
- 101001003006 Xenopus laevis Ferritin heavy chain B Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 6
- 108010002084 Apoferritins Proteins 0.000 description 6
- 102100022206 Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100029009 High mobility group protein HMG-I/HMG-Y Human genes 0.000 description 6
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 6
- 101000900394 Homo sapiens Cytochrome c oxidase subunit 4 isoform 1, mitochondrial Proteins 0.000 description 6
- 101000988643 Homo sapiens Humanin-like 8 Proteins 0.000 description 6
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 6
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 description 6
- 102100029086 Humanin-like 8 Human genes 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 208000027866 inflammatory disease Diseases 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 241000283086 Equidae Species 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 101000986380 Homo sapiens High mobility group protein HMG-I/HMG-Y Proteins 0.000 description 5
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 210000001789 adipocyte Anatomy 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 210000002826 placenta Anatomy 0.000 description 5
- -1 resveratrol Chemical class 0.000 description 5
- 210000002536 stromal cell Anatomy 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 108010085238 Actins Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 102000000546 Apoferritins Human genes 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 description 4
- 210000001552 airway epithelial cell Anatomy 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000007443 liposuction Methods 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 210000004003 subcutaneous fat Anatomy 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 108700026220 vif Genes Proteins 0.000 description 4
- 206010061666 Autonomic neuropathy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 108091006090 chromatin-associated proteins Proteins 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 208000005264 motor neuron disease Diseases 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 239000003900 neurotrophic factor Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000000634 Cytochrome c oxidase subunit IV Human genes 0.000 description 2
- 108090000365 Cytochrome-c oxidases Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 210000004322 M2 macrophage Anatomy 0.000 description 2
- 108010031099 Mannose Receptor Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 208000029033 Spinal Cord disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007914 intraventricular administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000001428 peripheral nervous system Anatomy 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940016667 resveratrol Drugs 0.000 description 2
- 235000021283 resveratrol Nutrition 0.000 description 2
- 239000003001 serine protease inhibitor Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 108091005957 yellow fluorescent proteins Proteins 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 102000042089 Actin family Human genes 0.000 description 1
- 108091080272 Actin family Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 1
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010050389 Cerebral ataxia Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010063094 Cerebral malaria Diseases 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 206010060774 Chondrosis Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 101710146663 EF-hand domain-containing protein D2 Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101150025028 FTL gene Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102000039539 Fos family Human genes 0.000 description 1
- 108091067362 Fos family Proteins 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000018802 High Mobility Group Proteins Human genes 0.000 description 1
- 101710176246 High mobility group protein Proteins 0.000 description 1
- 101150107737 Hmga1 gene Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101100111322 Homo sapiens BDNF gene Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000005431 Molecular Chaperones Human genes 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000003926 Myelitis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101100275485 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-4 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 108091078243 Rho family Proteins 0.000 description 1
- 102000042463 Rho family Human genes 0.000 description 1
- 101150036757 SPARC gene Proteins 0.000 description 1
- 101100481334 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) THP1 gene Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108700026518 Sequestosome-1 Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 101150018337 Serpinh1 gene Proteins 0.000 description 1
- 206010058571 Spinal cord infarction Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 101150069624 THP1 gene Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010001053 acute respiratory failure Diseases 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 210000001691 amnion Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 201000004559 cerebral degeneration Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- XPYGGHVSFMUHLH-UUSULHAXSA-N falecalcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(O)(C(F)(F)F)C(F)(F)F)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C XPYGGHVSFMUHLH-UUSULHAXSA-N 0.000 description 1
- 229950007545 falecalcitriol Drugs 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 208000010758 granulomatous inflammation Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000056482 human SIRT1 Human genes 0.000 description 1
- 102000011854 humanin Human genes 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000010438 iron metabolism Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 201000002818 limb ischemia Diseases 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000003498 protein array Methods 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 210000000246 tooth germ Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000001644 umbilical artery Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
Definitions
- the present invention relates to mesenchymal stem cells, anti-inflammatory agents and therapeutic agents for neurological diseases.
- Mesenchymal stem cells are pluripotent progenitor cells first isolated from bone marrow by Friedenstein in 1982 (see Non-Patent Document 1). It has been clarified that mesenchymal stem cells are present in various tissues such as bone marrow, umbilical cord, and fat, and mesenchymal stem cell transplantation is expected as a new therapeutic method for various intractable diseases. Recently, it is known that there are cells having the same function as stromal cells such as adipose tissue, placenta, umbilical cord, and fetal membrane. Therefore, mesenchymal stem cells may be referred to as stromal cells (Mesenchymal Cell).
- An object of the present invention is to provide a novel anti-inflammatory agent and a therapeutic agent for neurological diseases using mesenchymal stem cells under the above-mentioned circumstances.
- mesenchymal stem cells mesenchymal stem (stromal) cell; MSC
- MSC mesenchymal stem (stromal) cell
- [1] Mesenchymal stem cells characterized by high expression of SIRT1.
- [2] Mesenchymal stem cells characterized by high expression of BDNF.
- [3] The mesenchymal stem cell according to [1] or [2], which is derived from umbilical cord tissue.
- [5] A therapeutic agent for neurological diseases containing mesenchymal stem cells according to any one of [1] to [3].
- the present invention it is possible to provide a novel anti-inflammatory agent and a therapeutic agent for a neurological disease, and a novel therapeutic method for an inflammatory disease and a neurological disease.
- FIG. 1 is a diagram showing SIRT1 expression of umbilical cord-derived mesenchymal stem cells (Ctrl) and umbilical cord-derived mesenchymal stem cells (SIRT1) transfected with SIRT1.
- FIG. 2 is a diagram showing the inhibitory effect of co-culture of umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1 and THP1 cells on TNF ⁇ gene expression in THP1 cells. Is.
- FIG. 1 is a diagram showing SIRT1 expression of umbilical cord-derived mesenchymal stem cells (Ctrl) and umbilical cord-derived mesenchymal stem cells (SIRT1) transfected with SIRT1.
- FIG. 2 is a diagram showing the inhibitory effect of co-culture of umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal
- FIG. 3 is a diagram showing the inhibitory effect of co-culture of umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1 and THP1 cells on TNF ⁇ gene expression in THP1 cells.
- FIG. 4 is a diagram showing the effect of reducing the intracellular TNF ⁇ concentration of THP1 cells by co-culturing umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1 and THP1 cells. be.
- FIG. 4 is a diagram showing the effect of reducing the intracellular TNF ⁇ concentration of THP1 cells by co-culturing umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1 and T
- FIG. 5 is a diagram showing the TNF ⁇ concentration in the supernatant when co-cultured SIRT1-transfected umbilical cord-derived mesenchymal stem cells (SIRT1MSC group) and THP1.
- FIG. 6 shows a comparison of the inhibitory effect of co-culturing THP1 cells with umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1. It is a figure which shows.
- FIG. 6 shows a comparison of the inhibitory effect of co-culturing THP1 cells with umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1. It is a figure which shows.
- FIG. 7 is a diagram showing the BDNF concentration in the supernatant when THP1 is co-cultured with umbilical cord-derived mesenchymal stem cells (MSC group) or umbilical cord-derived mesenchymal stem cells (SIRT1 MSC group) transfected with SIRT1. ..
- the horizontal axis (h) indicates the time after transfection.
- FIG. 8 is a diagram showing a comparison of THP1 intracellular CD206 gene expression by co-culture of adipose-derived mesenchymal stem cells (ADMSC group) or SIRT1-transfected adipose-derived mesenchymal stem cells (SIRT1 ADMSC group) with THP1 cells. be.
- FIG. 9 is a diagram showing SIRT1 expression 24 hours after transfection in umbilical cord-derived mesenchymal stem cells (Ctrl) cultured in a serum-free medium and umbilical cord-derived mesenchymal stem cells (SIRT1) transfected with SIRT1.
- FIG. 10 is a diagram showing SIRT1 expression 72 hours after transfection in umbilical cord-derived mesenchymal stem cells (Ctrl) cultured in a serum-free medium and umbilical cord-derived mesenchymal stem cells (SIRT1) transfected with SIRT1.
- mesenchymal stem cells the mesenchymal stem cells, anti-inflammatory agents, and therapeutic agents for neurological diseases of the present invention will be described in detail.
- SIRT1 high expression mesenchymal stem cells
- the mesenchymal stem cells of the present invention are characterized by highly expressing SIRT1 (Sirtuin 1, sirtuin 1).
- SIRT belongs to class III of HDAC (histone deacetylase) and is an enzyme that deacetylates lysine residues of proteins in a NAD + -dependent manner.
- Human SIRT1 is known to be involved in many important processes in cells such as genomic stability, DNA repair, p53-mediated induction of apoptosis, fat production, and aging.
- SIRT1 is derived from mammals such as humans, monkeys, pigs, horses, cows, rabbits, sheep, goats, cats, dogs, and guinea pigs, and more preferably humans, monkeys, and mice. Is more preferable.
- One embodiment of the mesenchymal stem cell of the present invention may be a mesenchymal stem cell that highly expresses the SIRT1 gene and / or protein as compared with other cells.
- the mesenchymal stem cells need only express the SIRT1 gene and / or protein higher than the conventional mesenchymal stem cells, and preferably the SIRT1 gene expression is 10 times or more as compared with the conventional mesenchymal stem cells. It is preferably 100 times or more, more preferably 1000 times or more, and further preferably 5000 times or more.
- the mesenchymal stem cells of the present invention have a SIRT1 protein expression of 1.2 times or more, preferably 1.5 times or more, more preferably 2 times or more, still more preferably 5 times, as compared with the conventional mesenchymal stem cells. It should be higher than that.
- the conventional mesenchymal stem cells refer to mesenchymal stem cells obtained under conventional culture conditions (for example, culture in DMEM medium containing 10% FBS).
- the mesenchymal stem cells of the present invention need only express SIRT1 higher than other cells.
- the mesenchymal stem cells of the present invention are derived from human non-small cell lung cancer cells and human fetal lung.
- the SIRT1 gene is highly expressed as compared with normal fibroblasts or human small airway epithelial cells, preferably 10 as compared with human non-small cell lung cancer cells, human fetal lung-derived normal fibroblasts or human small airway epithelial cells. It may be more than twice, preferably 100 times or more, and more preferably 1000 times or more.
- the mesenchymal stem cells of the present invention have 1.2 times or more, preferably 1.5 times or more, SIRT1 protein expression as compared with human non-small cell lung cancer cells, human fetal lung-derived normal fibroblasts or human small airway epithelial cells. , More preferably 2 times or more, still more preferably 5 times or more.
- One embodiment of the mesenchymal stem cell of the present invention is a mesenchymal stem cell into which the SIRT1 gene has been introduced.
- the mesenchymal stem cell of the present invention is characterized in that it is a cell in which SIRT1 is highly expressed by artificially introducing the SIRT1 gene from the outside and forcibly expressing it.
- the SIRT1 gene may be transiently expressed in mesenchymal stem cells or may be stably expressed.
- the SIRT1 gene introduced into mesenchymal stem cells is derived from mammals such as humans, monkeys, pigs, horses, cows, rabbits, sheep, goats, cats, dogs, and guinea pigs, and among them, humans, monkeys, and mice. It is preferable that it is derived from humans, and it is more preferable that it is derived from humans.
- a gene registered as a SIRT1 gene in the gene database of National Center for Biotechnology Information (NCBI) can be mentioned, and for example, a human SIRT1 gene registered as NM_12238.4 can be mentioned as a preferable example.
- the SIRT1 gene to be introduced into mesenchymal stem cells may have a promoter sequence or the like necessary for expression in mesenchymal stem cells.
- the method for introducing the SIRT1 gene into mesenchymal stem cells is not particularly limited, and examples thereof include a method using synthesized mRNA and a method using a vector.
- a method for introducing the synthesized mRNA into mesenchymal stem cells a method known to those skilled in the art can be used, for example, a method using liposomes (many transfection reagents for this method are commercially available), Examples include the electroporation method.
- the vector in the method using the above vector can be appropriately selected depending on the intended purpose, and examples thereof include a viral vector and a non-viral vector.
- a viral vector and a non-viral vector.
- Specific examples of the above-mentioned virus vector include a retro virus vector, a lentivirus vector and the like.
- Specific examples of the non-viral vector include a plasmid vector and an episomal vector.
- the method for introducing the vector into mesenchymal stem cells is not particularly limited, and a known method can be appropriately selected depending on the intended purpose.
- the above vector may contain a marker gene for confirming the introduction of the SIRT1 gene.
- the marker gene refers to a gene that enables selection and selection of cells by introducing the marker gene into cells.
- Specific examples of the marker gene include a drug resistance gene, a fluorescent protein gene, a luminescent enzyme gene, a color-developing enzyme gene, and the like. These may be used alone or in combination of two or more.
- Specific examples of the above drug resistance genes include neomycin resistance gene, tetracycline resistance gene, canamycin resistance gene, zeosin resistance gene, hyglomycin resistance gene and the like.
- Specific examples of the fluorescent protein gene include a green fluorescent protein (GFP) gene, a yellow fluorescent protein (YFP) gene, a red fluorescent protein (RFP) gene, and the like.
- Specific examples of the luminescent enzyme gene include a luciferase gene and the like.
- Specific examples of the color-developing enzyme gene include ⁇ -galactosidase gene, ⁇ -glucuronidase gene, alkaline phosphatase gene and the like.
- One embodiment of the mesenchymal stem cell of the present invention is a mesenchymal stem cell in which the expression of SIRT1 gene and / or protein is enhanced by culturing under specific conditions or the like.
- SIRT1 expression of SIRT1 gene and / or protein
- a specific culture method capable of inducing the expression of SIRT1 which is said to induce the expression of SIRT1 by a polyphenol such as resveratrol, or by culturing in a specific medium or the like
- SIRT1 in mesenchymal stem cells It is also possible to obtain mesenchymal stem cells that induce expression and have high expression of SIRT1.
- the mesenchymal stem cells in which the expression of the SIRT1 gene and / or protein is enhanced by an immunological method using a cell sorter, magnetic beads, etc.
- the mesenchymal stem cells in which the expression of SIRT1 is higher is higher. Can be obtained.
- BDNF high expression mesenchymal stem cells
- the mesenchymal stem cells of the present invention are characterized by highly expressing BDNF (brain-developed neurotrophic factor).
- BDNF is a brain-derived neurotrophic factor and is a neurotrophic factor belonging to the neurotrophine family.
- Neurotrophins, especially BDNF have been shown to transport axons not only retrogradely but also antegradely and are released from nerve endings to affect postsynaptic cells.
- BDNF is derived from mammals such as humans, monkeys, pigs, horses, cows, rabbits, sheep, goats, cats, dogs, and guinea pigs, and is preferably derived from humans, monkeys, and mice. Is more preferable.
- One embodiment of the mesenchymal stem cell of the present invention may be a mesenchymal stem cell that highly expresses the BDNF gene and / or protein as compared with other cells.
- the mesenchymal stem cells need only express the BDNF gene and / or protein higher than those of the conventional mesenchymal stem cells, and are preferably compared with the mesenchymal stem cells obtained by the conventional mesenchymal stem cells.
- the BDNF gene expression should be 10-fold or higher, preferably 100-fold or higher, more preferably 1000-fold or higher, and even more preferably 5000-fold or higher.
- the mesenchymal stem cell of the present invention has a BDNF protein expression 1.1 times or more, more preferably 1.2 times or more, still more preferably 1.5 times or more higher than that of the conventional mesenchymal stem cell.
- the conventional mesenchymal stem cells refer to mesenchymal stem cells obtained under conventional culture conditions (for example, culture in DMEM medium containing 10% FBS).
- mesenchymal stem cell of the present invention is a mesenchymal stem cell in which the SIRT1 gene and / or protein is highly expressed and therefore the BDNF gene and / or protein associated therewith is highly expressed.
- Such mesenchymal stem cells may be cells in which the SIRT1 gene is artificially introduced from the outside and forcibly expressed, or the SIRT1 gene and / or protein is expressed by culturing under specific culture conditions or the like. It may be a cell in which the expression of SIRT1 gene and / or protein is enhanced originally.
- the mesenchymal stem cell of the present invention is a mesenchymal stem cell into which a BDNF gene has been introduced.
- the mesenchymal stem cell of the present invention is characterized in that it is a cell in which BDNF is highly expressed by artificially introducing a BDNF gene from the outside and forcibly expressing it.
- the BDNF gene may be transiently expressed in mesenchymal stem cells or may be stably expressed.
- the method for introducing the BDNF gene the same method as the above-mentioned method for introducing the SIRT1 gene can be used.
- the BDNF gene introduced into mesenchymal stem cells is derived from mammals such as humans, monkeys, pigs, horses, cows, rabbits, sheep, goats, cats, dogs, and guinea pigs, and among them, humans, monkeys, It is preferably derived from a mouse, more preferably from a human.
- a gene registered as a BDNF gene in the gene database of National Center for Biotechnology Information (NCBI) can be mentioned, and for example, a human BDNF gene registered as NM_170731 can be mentioned as a preferable example.
- NCBI National Center for Biotechnology Information
- the cells with high expression of the SIRT1 gene and / or protein are the LURAP1L, ACTA2, SQSTM1, COX4I1, PXN, RAC2, EFHD2, HMGA2, FOSL1, CD44, SPARC, SERPINH1, MTRNR2L8, HMGA1, FTH1 or FTL genes. And / or cells with high protein expression or high activity thereof. Therefore, in the present invention, the genes and / or proteins of LURAP1L, ACTA2, SQSTM1, COX4I1, PXN, RAC2, EFHD2, HMGA2, FOSL1, CD44, SPARC, SERPINH1, MTRNR2L8, HMGA1, FTH1 or FTL are highly expressed or their activities. Also includes mesenchymal stem cells with high protein.
- the mesenchymal stem cells of the present invention are defined in the same manner as SIRT1 and BDNF, and the mesenchymal stem cells of the present invention are LURAP1L, ACTA2, SQSTM1, COX4I1, PXN, RAC2, EFHD2, HMGA2, FOSL1, CD44, SPARC, as compared with the conventional mesenchymal stem cells.
- the expression and / or activity is more than twice as high as that of the conventional mesenchymal stem cells.
- the conventional mesenchymal stem cells refer to mesenchymal stem cells obtained under conventional culture conditions (for example, culture in DMEM medium containing 10% FBS).
- LURAP1L leucine-rich adapter protein 1 like
- ACTA2 ⁇ -smooth muscle actin, ⁇ -SMA belongs to the actin family. Actin is a highly conserved protein involved in various cell motility and is known to be expressed mainly in vascular smooth muscle.
- SQSTM1 (sequestosome1) is known to be a major protein that constitutes sequestosome.
- COXIV (COX-4, a subunit IV of cytochrome C oxidase) is known to be a subunit encoded in the nuclear genome of cytochrome C oxidase (COX), which is one of the human mitochondrial respiratory chain enzymes. ..
- PXN Planar adhesion gene
- cytoskeletal component involved in local attachment of actin membranes to the extracellular matrix, it interacts with multiple structural molecules and regulatory proteins to actin dynamics. Is known to change.
- RAC2 (ras-related C3 boutulinum toxin substrate 2) is a Rho family and is known to control various cell functions downstream of extracellular signals.
- EFHD2 EF-Hand Domestic Family Member D2, swiprosin-1
- T cell signals EF-Hand Domestic Family Member D2, swiprosin-1
- B cell lifespan EF-Hand Domestic Family Member D2, swiprosin-1
- EFHD2 EF-Hand Domestic Family Member D2, swiprosin-1
- swiprosin-1 is a relatively new intracellular protein that was first reported in 2004, and is associated with T cell signals and is associated with B cell lifespan. .. It is also known as a negative regulator of the canonical NF ⁇ B pathway.
- HMGA2 High Mobility Group AT-Hook 2
- AT-Hook 2 is a non-histone chromatin protein involved in the regulation of expression of various genes, and is known as an oncogene.
- FOSL1 is also known as FOS-related antigen 1 (FRA-1), is a leucine zipper (bZIP) transcription factor, and is known to be a protein of the Fos family.
- FOS-related antigen 1 FOS-related antigen 1
- bZIP leucine zipper
- CD44 is a single-transmembrane glycoprotein consisting of four functional domains, which are responsible for cell aggregation, retention of pericellular matrix, matrix-cell signaling, receptor-mediated uptake / degradation of hyaluronic acid, cell migration, etc. It is known to be involved in various cell functions including.
- SPARC Secret Protein Acid and Rich in System
- ECM intracellular-extracellular matrix
- the SPARC gene is involved in tissue development, remodeling, and fibrosis. It is known to encode a functional glycoprotein.
- SERPINH1 (Serpin Family H Member 1) belongs to the serpin superfamily of serine protease inhibitors (serine proteinase inhibitors), and its expression is induced by heat shock.
- the SERPINH1 protein is localized in the endoplasmic reticulum cavity and binds to collagen. It is thought to be a molecular chaperone involved in the maturation of collagen molecules.
- MTRNR2L8 (MT-RNR2 Like Protein 8) belongs to humanin family and is known to act as a neuroprotective and anti-apoptotic factor.
- HMGA1 High mobility group protein isoform I
- non-histone chromatin protein non-histone chromatin protein
- It is known as a structural transcription factor that can produce.
- FTH1 (Ferritin Heavy Chain 1) encodes a heavy chain (Heavy Chain subunit) peculiar to ferritin, which is a major intracellular iron storage protein, and affects the rate of iron uptake and release in various tissues. It is believed to be giving.
- FTL Fluorescence light chain
- the mesenchymal stem cell has an ability to differentiate into one or more cells belonging to the mesenchymal system (osteocytes, myocardial cells, chondrocytes, tendon cells, fat cells, etc.), and maintains the ability. It means a cell that can proliferate.
- mesenchymal stem cell used in the present invention means the same cell as a stromal cell, and does not particularly distinguish between the two. It may also be simply referred to as mesenchymal cells.
- tissues containing mesenchymal stem cells include adipose tissue, umbilical cord, bone marrow, umbilical cord blood, endometrial membrane, placenta, amniotic membrane, chorion, decidua, dermatitis, skeletal muscle, bone membrane, tooth follicles, and periodontal ligament.
- tissue containing mesenchymal stem cells include adipose tissue, umbilical cord, bone marrow, umbilical cord blood, endometrial membrane, placenta, amniotic membrane, chorion, decidua, dermatitis, skeletal muscle, bone membrane, tooth follicles, and periodontal ligament.
- examples include dental pulp and tooth germ.
- adipose tissue-derived mesenchymal stem cells mean mesenchymal stem cells contained in adipose tissue, and may be referred to as adipose tissue-derived stromal cells.
- adipose tissue-derived mesenchymal stem cells adipose tissue-derived mesenchymal stem cells, umbilical band-derived mesenchymal stem cells, bone marrow-derived mesenchymal stem cells, and placenta-derived mesenchymal stem cells
- Leaf-based stem cells and dental pulp-derived mesenchymal stem cells are preferable, adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells are more preferable, and umbilical cord-derived mesenchymal stem cells are most preferable.
- the mesenchymal stem cells in the present invention may be derived from the same species as the subject (subject) to be treated, or may be derived from a different species.
- Examples of the species of mesenchymal stem cells in the present invention include humans, horses, cows, sheep, pigs, dogs, cats, rabbits, mice, and rats, and preferably cells derived from the same species as the subject to be treated. ..
- the mesenchymal stem cells in the present invention may be derived from a subject (subject) to be treated, that is, an autologous cell, or may be derived from another subject of the same species, that is, an allogeneic cell. It is preferably an allogeneic cell.
- mesenchymal stem cells are less likely to cause rejection of allogeneic subjects, pre-prepared donor cells are expanded and cryopreserved in the mesenchymal system in the disease therapeutic agent of the present invention. It can be used as a stem cell. Therefore, the mesenchymal stem cells in the present invention can be easily commercialized and can obtain a stable and constant effect as compared with the case where self-mesenchymal stem cells are prepared and used. It is more preferable that they are allogeneic.
- the mesenchymal stem cell means an arbitrary cell population including the mesenchymal stem cell.
- the cell population is at least 20% or more, preferably 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 93%, 96%, 97%, 98. % Or 99% are mesenchymal stem cells.
- the umbilical cord is a white tubular tissue that connects the fetal and the placenta, and is composed of umbilical veins, umbilical arteries, glue-like tissues (Wharton's Jelly), umbilical cord matrix itself, and the like, and is composed of mesenchymal stem cells. Including a lot.
- the umbilical cord is preferably obtained from an animal of the same species as the subject (administration target) using the therapeutic agent for the disease of the present invention, and more preferably for humans in consideration of administering the therapeutic agent for the disease of the present invention to humans.
- Umbilical band is a white tubular tissue that connects the fetal and the placenta, and is composed of umbilical veins, umbilical arteries, glue-like tissues (Wharton's Jelly), umbilical cord matrix itself, and the like, and is composed of mesenchymal stem cells. Including a lot.
- the umbilical cord is preferably obtained from an animal of the same species as the subject (administration target
- adipose tissue means a tissue containing stromal cells including fat cells and microvascular cells, and is, for example, a tissue obtained by surgically excising or aspirating subcutaneous fat of a mammal.
- Adipose tissue can be obtained from subcutaneous fat. It is preferably obtained from an animal of the same species as the adipose tissue-derived mesenchymal stem cell to be administered, which will be described later, and more preferably human subcutaneous fat in consideration of administration to humans.
- the subcutaneous fat supply individual may be alive or dead, but the adipose tissue used in the present invention is preferably a tissue collected from a surviving individual.
- liposuction When collected from an individual, liposuction includes, for example, PAL (power assist) liposuction, erconia laser liposuction, body jet liposuction, etc., and ultrasonic waves from the viewpoint of maintaining the state of cells. It is preferable not to use.
- PAL power assist
- erconia laser liposuction erconia laser liposuction
- body jet liposuction etc.
- ultrasonic waves from the viewpoint of maintaining the state of cells. It is preferable not to use.
- the bone marrow is a parenchyma that fills the lumen of bone and is a hematopoietic organ. Cerebrospinal fluid exists in the bone marrow, and the cells existing in the fluid are called bone marrow cells.
- Bone marrow cells include mesenchymal stem cells, hematopoietic stem cells, vascular endothelial progenitor cells and the like, as well as red blood cells, granulocytes, megakaryocytes, lymphocytes, adipocytes and the like. Bone marrow cells can be harvested from, for example, human ilium, long bone, or other bone.
- tissue-derived mesenchymal stem cells such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, and bone marrow-derived mesenchymal stem cells are referred to as adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells, respectively.
- adipose tissue-derived mesenchymal stem cells and umbilical cord-derived mesenchymal stem cells respectively.
- It means an arbitrary cell population including mesenchymal stem cells derived from each tissue such as stem cells and mesenchymal stem cells derived from bone marrow.
- the cell population is at least 20% or more, preferably 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 93%, 96%, 97%, 98.
- tissue-derived mesenchymal stem cells such as adipose tissue-derived mesenchymal stem cells, umbilical cord-derived mesenchymal stem cells, and bone marrow-derived mesenchymal stem cells.
- the mesenchymal stem cells in the present invention have, for example, growth characteristics (eg, population doubling ability from passage to aging, doubling time), nuclei.
- Type analysis eg, normal nuclear type, maternal or neonatal lineage
- surface marker expression by flow cytometry eg, FACS analysis
- immunohistochemistry and / or immunocytochemistry eg, epitope detection
- Gene expression profiling eg, gene chip array; polymerase chain reaction such as reverse transcription PCR, real-time PCR, conventional PCR
- miRNA expression profiling eg, protein array, protein secretion such as cytokine (eg, plasma coagulation analysis, ELISA, cytokine array) ), Metabolites (metabolome analysis), other methods known in the art, and the like.
- the method for preparing mesenchymal stem cells of the present invention having a high expression level of SIRT1 is not particularly limited, but can be prepared as follows, for example. That is, cells having a high SIRT1 expression level can be obtained by separating and culturing mesenchymal stem cells from tissues such as fat, umbilical cord, and bone marrow according to a method known to those skilled in the art, and introducing the SIRT1 gene. can.
- the description in the section "SIRT1 high expression mesenchymal stem cells” can be applied. It is also possible to obtain mesenchymal stem cells having a high expression level of SIRT1 by culturing using a specific medium such as polyphenol such as resveratrol.
- the cell population obtained by this gene transfer or induction it is preferable that 50% or more of the cell population is a cell having a high SIRT1 expression level, and more preferably 70% or more is a cell having a high SIRT1 expression level. , 80% or more are cells having a high SIRT1 expression level, more preferably 90% or more are cells having a high SIRT1 expression level, and substantially uniform cells having a high SIRT1 expression level. Most preferably it is a cell population.
- a method for preparing mesenchymal stem cells having a high expression level of SIRT1 will be specifically described.
- the mesenchymal stem cells of the present invention may be defined as cells having the following characteristics in addition to having the above-mentioned characteristics (high expression of SIRT1 gene and / or protein, etc.); (1) Shows adhesiveness to plastic under culture conditions in a standard medium. (2) The surface antigens CD44, CD73, and CD90 are positive, CD31, CD34, and CD45 are negative, and (3) they can be differentiated into bone cells, adipocytes, and chondrocytes under culture conditions.
- the anti-inflammatory agent and the therapeutic agent for neurological diseases of the present invention contain the above-mentioned SIRT1 high-expressing mesenchymal stem cells and / or BDNF high-expressing mesenchymal stem cells of the present invention. According to the anti-inflammatory agent of the present invention, inflammation can be prevented, suppressed or treated. Further, according to the therapeutic agent for neurological diseases of the present invention, neurological diseases can be prevented, suppressed or treated.
- the above description of the section on mesenchymal stem cells can be applied to the mesenchymal stem cells contained in the anti-inflammatory agent and the therapeutic agent for neurological diseases of the present invention.
- the routes of administration of the anti-inflammatory agent and the therapeutic agent for neurological diseases of the present invention to a subject are oral administration, subcutaneous administration, intramuscular administration, intravenous administration, intraarterial administration, intravenous umbilical cord administration, intraventricular administration, and intrathecal administration.
- intraarterial administration intravenous administration and intraventricular administration are preferable, and from the viewpoint of reducing the burden on the subject, intravenous administration and intramuscular administration are more preferable.
- Administration and intranasal administration are preferable.
- the dose (dose) thereof is the patient's condition (weight, age, symptom, physical condition, etc.) and the dosage form of the anti-inflammatory agent and the therapeutic agent for neurological diseases of the present invention.
- the amount is large from the viewpoint of exerting a sufficient therapeutic effect of the anti-inflammatory agent and the therapeutic agent for neurological diseases, while the amount is preferable from the viewpoint of suppressing the occurrence of side effects. The smaller the number, the more preferable.
- the number of cells is 1 ⁇ 10 3 to 1 ⁇ 10 12 cells / time, preferably 1 ⁇ 10 4 to 1 ⁇ 10 11 cells / time, more preferably 1 ⁇ 10 5 to 1 ⁇ 10 10 pieces / time, more preferably 5 ⁇ 10 6 to 1 ⁇ 10 9 pieces / time.
- the dose per patient's body weight is 1 ⁇ 10 to 5 ⁇ 10 10 pieces / kg, preferably 1 ⁇ 10 2 to 5 ⁇ 10 9 pieces / kg, and more preferably 1 ⁇ 10 3 to 5 ⁇ 10. 8 pieces / kg, more preferably 1 ⁇ 10 4 to 5 ⁇ 10 7 pieces / kg.
- the number of cells is 1 ⁇ 10 3 to 1 ⁇ 10 11 cells / time, preferably 1 ⁇ 10 4 to 1 ⁇ 10 10 cells / time, more preferably 1 ⁇ 10 5 to 1 ⁇ . 10 9 pieces / time, more preferably 5 ⁇ 10 5 to 5 ⁇ 10 8 pieces / time.
- the dose per patient's body weight is 1 ⁇ 10 to 5 ⁇ 10 10 pieces / kg, preferably 1 ⁇ 10 2 to 5 ⁇ 10 9 pieces / kg, and more preferably 1 ⁇ 10 3 to 5 ⁇ 10. 8 pieces / kg, more preferably 1 ⁇ 10 4 to 5 ⁇ 10 7 pieces / kg.
- this dose may be administered as a single dose in a plurality of times, or this dose may be administered in a plurality of times.
- the anti-inflammatory agent and the therapeutic agent for neurological diseases of the present invention may be administered together with one or more other agents.
- Other agents include any agent that can be used as an anti-inflammatory agent or as a therapeutic agent for neurological disorders.
- the mesenchymal stem cells of the present invention can be used for various inflammatory diseases, and specific diseases include chondrosis, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, osteoarthritis, gout, psoriasis, and multiple diseases.
- Sclerosis muscular atrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, congestive heart failure, stroke, aortic valve stenosis, renal failure, ulcer, pancreatitis, allergy, fibrosis, anemia, atherosclerosis, re-stenosis , Chemotherapy / radiation-related complications, type I diabetes, type II diabetes, autoimmune hepatitis, hepatitis C, primary biliary cirrhosis, primary sclerosing cholangitis, fulminant hepatitis, celiac disease, nonspecific colon Flame, Crohn's disease, Allergic conjunctivitis, Diabetic retinopathy, Schegren's syndrome, Glaccomitis Allergic rhinitis, Asthma, Asbestos, Syllabic, Chronic obstructive pulmonary disease, Chronic granulomatous inflammation, Cystic fibrosis, Sarcoidosis, Gloscular nephritis,
- the mesenchymal stem cells of the present invention can be used for various neurological diseases, and specific diseases include autonomic neuropathy, Hornel syndrome, polyline atrophy, autonomic neuropathy such as pure autonomic neuropathy, and chronic pain. , Neuropathic pain, pain such as complex local pain syndrome, ischemic stroke, transient cerebral ischemic attack, intracerebral hemorrhage, stroke such as submucosal hemorrhage (cerebral vascular accident), Alzheimer's disease, cerebrovascular cognition Diseases, Levi body dementia, HIV-related dementia, dementia such as frontotemporal dementia, cerebral palsy syndrome such as spasmodic syndrome, atetose or dyskinesia syndrome and ataxia syndrome, submucosal bleeding, intracerebral bleeding, brain Intracranial bleeding such as indoor bleeding, hypoxia-ischemia, ischemic stroke, hypoglycemia, hypersodiumemia, hyponatremia, hypomagnesemia, congenital metabolic disorders, etc., neonatal
- the present invention also includes a method for treating an inflammatory disease or a neurological disease, which comprises using the above-mentioned mesenchymal stem cells having a high expression of SIRT1.
- the present invention also includes a method for treating an inflammatory disease or a neurological disease, which comprises using the above-mentioned mesenchymal stem cells having a high expression of BDNF.
- the therapeutic method of the present invention can also be said to be a method characterized by using the above-mentioned anti-inflammatory agent and / or neurological disease therapeutic agent of the present invention.
- the above-mentioned explanations for mesenchymal stem cells, anti-inflammatory agents and therapeutic agents for neurological diseases can be applied.
- Umbilical cord-derived mesenchymal stem cells (Promocell) were seeded in culture vessels at 15,000 cells / cm 2 . After 24-48 hours, cells were confirmed to be 70-90% confluent and transfected with SIRT1 mRNA. Specifically, mRNA is diluted with Optimem medium (manufactured by Thermo Fisher), transfection reagent (manufactured by Mirus, Trans-IT® liposome) is added, and the mixture is gently stirred with a pipette, and then from the outside of the tube. Mix by tapping to create mRNA-liposome complex.
- Optimem medium manufactured by Thermo Fisher
- transfection reagent manufactured by Mirus, Trans-IT® liposome
- a 1: 2000 dilution of the secondary antibody (Abcam, ab150113) was reacted for 1 hour. After the reaction, the membrane was washed, and the expression level of SIRT1 was confirmed by an image taken by Chemidoc imager (BioRad) (Fig. 1). The expression levels of untransfected umbilical cord-derived mesenchymal stem cells (Ctrl) at 24 hours and 72 hours after transfection were shown (FIG. 1). In addition, a rhodamine-binding antibody (BioRad, 12004166) was used for ⁇ -tubulin as an internal standard.
- THP1 which is a human-derived monocyte cell
- PMA Holbol 12-myristate 13-acetate
- product number 162-23591 Fujifilm Wako Pure Chemical Industries, Ltd.
- ⁇ SC Umbilical cord-derived mesenchymal stem cells
- SIRT1 ⁇ SC umbilical cord-derived mesenchymal stem cells transfected with SIRT1 mRNA
- LPS lipopolysaccharide
- SIRT1 ⁇ SC ⁇ SC-SIRT1 ⁇ SC group
- Fig. 2 TNF ⁇ gene expression was increased with LPS stimulation (LPS group), but its expression was suppressed by co-culture with ⁇ SC ( ⁇ SC group). Its expression was further suppressed by co-culturing with SIRT1 ⁇ SC (SIRT1 ⁇ SC group) (Fig. 2). From this, it was found that ⁇ SC is effective against inflammation, and in particular, ⁇ SC that highly expresses SIRT1 has an excellent anti-inflammatory effect.
- SIRT1 ⁇ SC cells prepared by the method described in the section of Test 1 and then cryopreserved by a conventional method were used. Specifically, cells that had been thawed and preliminarily cultured in a culture flask for 3 or 4 days were collected, seeded in Transwell, and used.
- THP1 was seeded on a 12-well plate at 30,000 cells / cm 2 and 200 nM PMA was added and cultured for 4 days.
- ⁇ SC and SIRT1 ⁇ SC were seeded and cultured at 40,000 cells / cm 2 on 0.4 ⁇ m Transwell inserts the day before co-culture.
- 1 ⁇ g / mL LPS was added to the wells of THP1 and ⁇ SC, and Transwells seeded with ⁇ SC were placed on the wells seeded with THP1 and co-cultured for 2 days (37 ° C., 2% CO). 2 ).
- the THP1 cytolysis was collected, and the expression of the TNF ⁇ gene was quantified by qRT-PCR in the same manner as described above. After centrifuging the culture supernatant at 400xG for 5 minutes, the TNF ⁇ concentration in the supernatant was measured by ELISA.
- SIRT1 ⁇ SC cells prepared by the method described in the section of Test 1 and then cryopreserved by a conventional method were used. Specifically, cells that had been thawed and preliminarily cultured in a culture flask for 3 or 4 days were collected, seeded in Transwell, and used.
- TNF ⁇ gene expression was increased with LPS stimulation (LPS group), but its expression was suppressed by co-culture with ⁇ SC ( ⁇ SC group). Its expression was further suppressed by co-culturing with SIRT1 ⁇ SC (SIRT1 ⁇ SC group) (Fig. 3).
- the TNF ⁇ concentration was also increased by LPS stimulation (LPS group) as compared with the untreated group, but was suppressed by co-culture of ⁇ SC ( ⁇ SC group) or SIRT1 ⁇ SC (SIRT1 ⁇ SC group), and SIRT1 ⁇ SC was higher than that of the ⁇ SC group.
- the inhibitory effect was high (Fig. 4). Similar to Test 3, ⁇ SC was effective against inflammation, and it was confirmed that ⁇ SC expressing SIRT1 in particular had an excellent anti-inflammatory effect.
- THP1 was seeded on a 12-well plate at 30,000 cells / cm 2 , 100 nMPMA was added, and the cells were cultured for 4 days.
- ⁇ SC and SIRT1 ⁇ SC were seeded and cultured at 40,000 cells / cm 2 on 0.4 ⁇ m Transwell inserts the day before co-culture.
- 1 ⁇ g / mL LPS was added to the wells of THP1 and ⁇ SC to stimulate LPS, and the transwells seeded with ⁇ SC were placed on the wells seeded with THP1 and co-cultured for 2 days (37 ° C.).
- THP1 was seeded on a 12-well plate at 30,000 cells / cm 2 , 200 nMPMA was added, and the cells were cultured for 4 days.
- ⁇ SC and SIRT1 ⁇ SC were seeded and cultured at 40,000 cells / cm 2 on 0.4 ⁇ m Transwell inserts the day before co-culture.
- 1 ⁇ g / mL LPS was added to the wells of THP1 and ⁇ SC to stimulate LPS, and the transwells seeded with ⁇ SC were placed on the wells seeded with THP1 and co-cultured for 2 days (37 ° C.).
- TNF ⁇ gene expression was increased with LPS stimulation (LPS group), but its expression was suppressed by co-culture with ⁇ SC ( ⁇ SC group). Its expression was further suppressed by co-culturing with SIRT1 ⁇ SC (SIRT1 ⁇ SC group) (Fig. 6).
- SIRT1 ⁇ SC cells prepared by the method described in Test 1 and then cryopreserved by a conventional method were used. Specifically, cells that had been thawed and preliminarily cultured in a culture flask for 3 or 4 days were collected, seeded in Transwell, and used.
- Umbilical cord-derived mesenchymal stem cells ( ⁇ SC) and umbilical cord-derived mesenchymal stem cells (SIRT1 ⁇ SC) transfected with SIRT1 mRNA were seeded in 6-well plates (Corning, # 3335) at 5,000 cells / cm 2 respectively, and 10 Incubation was carried out in% FBS DMEM medium (Sigma, # D5796) for 24 hours, 48 hours and 72 hours.
- SIRT1 ⁇ SC S was found to have a higher expression of BDNF than ⁇ SC ( ⁇ ) (Fig. 7).
- the BDNF concentration in SIRT1 ⁇ SC was 4.45 times after culturing for 24 hours, 6.30 times after culturing for 48 hours, and 7.81 times after culturing for 72 hours.
- the expression of BDNF gene was quantified by qRT-PCR, the expression of BDNF in SIRT1 ⁇ SC after culturing for 72 hours was 1.54 times that of ⁇ SC.
- the primer sets of SEQ ID NOs: 5 and 6 were used for qRT-PCR.
- BDNF is a factor that acts on some neurons in the central and peripheral nervous systems and promotes the maintenance, growth, and differentiation of neurons (Nature 374 (6521): 450-3), and is important for long-term memory. It is also known that there is (Proc. Natl. Acad. Sci. USA 105 (7): 2711-6). SIRT1 ⁇ SC, which has an increased expression level of BDNF, is considered to be effective in treating diseases of the central nervous system and peripheral nervous system, especially in neurological diseases that are expected to be improved by maintenance, growth, and differentiation of neurons. Be done. In addition, from the results of this experiment, it can be said that it is preferable to use cells cultured for 24 hours to 72 hours after transfection for administration for disease treatment.
- Fat-derived mesenchymal stem cells (Promocell) were seeded in culture vessels at 15,000 cells / cm 2 . After 24-48 hours, cells were confirmed to be 70-90% confluent and transfected with SIRT1 mRNA as in Test 1. In addition, the same examination as in Test 2 was carried out, and it was confirmed that SIRT1 was expressed in adipose-derived mesenchymal stem cells.
- THP1 Changes in THP1 gene expression by co-culture with SIRT1-expressing fat-derived mesenchymal stem cells
- THP1 was seeded on a 12-well plate at 30,000 cells / cm 2 , 200 nM PMA was added, and the cells were cultured for 4 days.
- Fat-derived mesenchymal stem cells hereinafter referred to as "AD ⁇ SC”
- SIRT1AD ⁇ SC fat-derived mesenchymal stem cells transfected with SIRT1 mRNA
- LPS group Compared with no LPS stimulation (untreated group), CD206 gene expression was increased with LPS stimulation (LPS group). The expression was increased in the co-culture with SIRT1AD ⁇ SC (SIRT1AD ⁇ SC group) as compared with the co-culture with AD ⁇ SC (AD ⁇ SC group) (Fig. 8). It was found that co-culture with AD ⁇ SC, which highly expresses SIRT1, increased the expression of the CD206 gene of THP1.
- SIRT1 ⁇ SC cells prepared by the method described in Test 1 and then cryopreserved by a conventional method were used. Specifically, cells that had been thawed and preliminarily cultured in a culture flask for 3 or 4 days were collected, seeded in Transwell, and used.
- CD206 also called a macrophage mannose receptor (MMR)
- MMR macrophage mannose receptor
- THP1 macrophage mannose receptor
- ⁇ SC and SIRT1 ⁇ SC were seeded and cultured in GM2 medium (Promocell), A549 and MRC-5 in DMEM medium containing 10% FBS, and SAEC in the recommended medium of Ronza at the recommended seeding density of each cell. ..
- the primer sets of SEQ ID NOs: 1 and 2 shown in Test 1 were used for quantitative PCR.
- Table 1 shows the mRNA expression level of SIRT1 in each cell when the mRNA expression level of SIRT1 of ⁇ SC was 1.
- Ctrl is a control without electroporation (without mRNA)
- E is a control with electroporation (without mRNA)
- EGFP is a sample into which GFP mRNA is introduced by the electroporation method
- SIRT1 is electroporation. A sample into which SIRT1 mRNA was introduced by the electroporation method is shown.
- SIRT1 gene expression was confirmed in cells cultured for 24 hours and cells cultured for 72 hours after transfection of SIRT1 mRNA by the electroporation method. As described above, it was clarified that SIRT1 mRNA can be appropriately introduced into serum-free medium-cultured MSCs by using the electroporation method.
- an anti-inflammatory agent and a therapeutic agent for neurological diseases can be provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
[2]BDNFを高発現することを特徴とする、間葉系幹細胞。
[3]臍帯組織由来である、[1]又は[2]に記載の間葉系幹細胞。
[4][1]から[3]のいずれかに記載の間葉系幹細胞を含有する抗炎症剤。
[5][1]から[3]のいずれかに記載の間葉系幹細胞を含有する神経疾患治療剤。
(SIRT1高発現間葉系幹細胞)
本発明の間葉系幹細胞は、SIRT1(Sirtuin1、サーチュイン1)を高発現することを特徴とする。SIRT(Sirtuin,サーチュイン)はHDAC(ヒストン脱アセチル化酵素)のクラスIIIに属しており、タンパク質のリジン残基をNAD+依存的に脱アセチル化する酵素である。ヒトSIRT1は、ゲノムの安定性、DNA修復、p53を介したアポトーシスの誘導、脂肪生成、老化等、細胞における多くの重要なプロセスに関わることが知られている。
本発明の間葉系幹細胞は、BDNF(brain-derived neurotrophic factor)を高発現することを特徴とする。BDNFは、脳由来神経栄養因子であり、ニューロトロフィンファミリーに属する神経栄養因子である。ニューロトロフィン、特にBDNFは、軸索を逆行性だけでなく順行性にも輸送され神経終末から放出されてシナプス後細胞に対しても影響を及ぼすことが明らかにされている。
SIRT1の発現量が高い本発明の間葉系幹細胞の調製方法は特に限定されないが、例えば以下のようにして調製することができる。すなわち、脂肪、臍帯、骨髄等の組織から、当業者に公知の方法に従って、間葉系幹細胞を分離、培養し、SIRT1遺伝子を導入することにより、SIRT1の発現量が高い細胞を取得することができる。間葉系幹細胞へのSIRT1遺伝子の導入方法については、「SIRT1高発現間葉系幹細胞」の項における説明を適用できる。また、レスベラトロール等のポリフェノール等、特定の培地を用いた培養により、SIRT1の発現量が高い間葉系幹細胞を取得することもできる。
(1)標準培地での培養条件で、プラスチックに接着性を示す、
(2)表面抗原CD44、CD73、CD90が陽性であり、CD31、CD34、CD45が陰性であり、及び
(3)培養条件にて骨細胞、脂肪細胞、軟骨細胞に分化可能。
本発明の抗炎症剤及び神経疾患治療剤は、上述した本発明の、SIRT1高発現間葉系幹細胞及び/又はBDNF高発現間葉系幹細胞を含有する。本発明の抗炎症剤によると、炎症を予防、抑制もしくは治療にすることができる。また、本発明の神経疾患治療剤によると、神経疾患を予防、抑制もしくは治療することができる。本発明の抗炎症剤及び神経疾患治療剤が含有する間葉系幹細胞については、上記間葉系幹細胞の項の説明を適用できる。
臍帯由来間葉系幹細胞(Promocell社)を、15,000cells/cm2で培養容器に播種した。24~48時間後、細胞が70-90%のコンフルエント状態であることを確認し、SIRT1のmRNAをトランスフェクションした。具体的には、mRNAをOptimem培地(サーモフィッシャー社製)で希釈し、トランスフェクション試薬(Mirus社製、Trans-IT(登録商標)liposome)を加え、ピペットで優しく攪拌した後、チューブの外側からタップすることで混合し、mRNA-リポソーム複合体を作製した。室温で2-5分間静置して安定化させたのち、培養細胞を播種した容器に全体的に少しずつ、滴下した。その後、37℃で24~72時間培養した。SIRT1遺伝子発現は、配列番号1及び2のプライマーセットを用いてPCRによって確認した。
SIRT1のmRNAをトランスフェクションした細胞をRIPAバッファー(サーモフィッシャ―社、89900)により溶解した。得られた細胞溶解物を電気泳動(SDS-PAGE法)した後に、ゲル上のたんぱく質をニトロセルロース膜にブロッティングした。その後、1%BSA溶液で1時間ブロッキングした後、SIRT1抗体(アブカム社、ab104833)の1:500希釈液に室温で1時間浸した。なお、SDS-PAGE及びブロッティングにはサーモフィッシャー社のキット(NW04120)を使用した。メンブレンをTBSTで洗浄した後、二次抗体(アブカム社、ab150113)の1:2000希釈液を1時間反応させた。反応後、メンブレンを洗浄し、Chemidoc imager(BioRad社)での画像により、SIRT1の発現量を確認した(図1)。なお、トランスフェクションを行っていない臍帯由来間葉系幹細胞をコントロール(Ctrl)として、トランスフェクション後24時間及び72時間における発現量を示した(図1)。また、内部標準としてのβチューブリンに対してはローダミン結合抗体(BioRad社、12004166)を使用した。
ヒト由来単球細胞であるTHP1(以下「THP1」という)を30,000cells/cm2で12ウェルプレートに播種して、ホルボール12-ミリステート13-アセテート(Phorbol 12-myristate 13-acetate、以下「PMA」という、品番162-23591、富士フイルム和光純薬株式会社)を100nM添加して、4日間培養した。臍帯由来間葉系幹細胞(以下「МSC」という)及びSIRT1のmRNAをトランスフェクションした臍帯由来間葉系幹細胞(以下「SIRT1МSC」という)は共培養の前日に0.4μmトランズウェルインサート上に40,000cells/cm2で播種して培養した。共培養開始時に、THP1及びМSCのウェルに1ug/mLのリポポリサッカライド(Lipopolysaccharide、以下「LPS」という、InvivoGen社製、品番14874-24)を添加し、МSCを播種したトランズウェルを、THP1を播種したウェル上に設置し、3日間共培養した(37℃、2%CO2)。その後、THP1細胞溶解物(細胞ライセート、cell lysate)を回収し、TNFα遺伝子の発現をQuantstudio1(サーモフィッシャー社)を用い、qRT-PCRにて定量した。その際に配列番号3及び4のプライマーセットを用いた。
THP1を30,000cells/cm2で12ウェルプレートに播種して、200nMのPMAを添加して、4日間培養した。МSC及びSIRT1МSCは共培養の前日に0.4μmトランズウェルインサート上に40,000cells/cm2で播種して培養した。共培養開始時に、THP1及びМSCのウェルに1μg/mLのLPSを添加し、МSCを播種したトランズウェルを、THP1を播種したウェル上に設置し、2日間共培養した(37℃,2%CO2)。その後、THP1細胞溶解物を回収し、TNFα遺伝子の発現を上記と同様にqRT-PCRにて定量した。また、培養上清を400xGで5分間遠心分離した後、上清中のTNFα濃度をELISAにより測定した。なお、SIRT1МSCは、試験1の項に記載した方法にて作成した後、常法にて凍結保存した細胞を使用した。具体的には、解凍し、培養フラスコにて3もしくは4日間予備的に培養を行った細胞を回収してトランズウェルに播種し、使用した。
THP1を30,000cells/cm2で12ウェルプレートに播種して、100nMPMAを添加し、4日間培養した。МSC及びSIRT1МSCは共培養の前日に0.4μmトランズウェルインサート上に40,000cells/cm2で播種して培養した。共培養開始時に、THP1及びМSCのウェルに1μg/mLのLPSを添加しLPS刺激を行い、МSCを播種したトランズウェルを、THP1を播種したウェル上に設置し、2日間共培養した(37℃、2%CO2)。その後、トランズウェルを取り除き、THP1を、LPSを含まない培地に交換し、THP1単独で更に1日培養した。培養上清を400xGで5分間遠心分離した後、上清中のTNFα濃度をELISAにより測定した。TNFα濃度は、SIRT1МSCとの共培養により下がった(図5)。以上から、SIRT1を高発現するМSCは優れた抗炎症効果を有することがわかった。なお、SIRT1МSCは、試験1に記載した方法にて作成した後、常法にて凍結保存した細胞を使用した。具体的には、解凍し、培養フラスコにて3もしくは4日間予備的に培養を行った細胞を回収してトランズウェルに播種し、使用した。
THP1を30,000cells/cm2で12ウェルプレートに播種して、200nMPMAを添加して、4日間培養した。МSC及びSIRT1МSCは共培養の前日に0.4μmトランズウェルインサート上に40,000cells/cm2で播種して培養した。共培養開始時に、THP1及びМSCのウェルに1μg/mLのLPSを添加しLPS刺激を行い、МSCを播種したトランズウェルを、THP1を播種したウェル上に設置し、2日間共培養した(37℃、2%CO2)。その後、トランズウェルを取り除き、THP1を、LPSを含まない培地に交換し、THP1単独で更に1日培養した。その後、THP1細胞溶解物を回収し、TNFα遺伝子の発現を上記試験3と同様にqRT-PCRにて定量した。LPS刺激無し(未処理群)と比較し、LPS刺激あり(LPS群)ではTNFα遺伝子発現が上昇したが、МSCとの共培養によりその発現は抑制された(МSC群)。SIRT1МSCとの共培養によりその発現は更に抑制された(SIRT1МSC群)(図6)。試験3と同様に、МSCは炎症に対して有効であり、特にSIRT1を高発現するМSCは優れた抗炎症効果を有することがわかった。なお、SIRT1МSCは、試験1に記載した方法にて作成した後、常法にて凍結保存した細胞を使用した。具体的には、解凍し、培養フラスコにて3もしくは4日間予備的に培養を行った細胞を回収してトランズウェルに播種し、使用した。
臍帯由来間葉系幹細胞(МSC)及びSIRT1のmRNAをトランスフェクションした臍帯由来間葉系幹細胞(SIRT1МSC)を、それぞれ6ウェルプレート(Corning,#3335)に5,000cells/cm2で播種し、10%FBS DMEM培地(Sigma,#D5796)で24時間、48時間及び72時間培養を行った。培養後、培養上清を400xGで5分間遠心分離した後、上清中のBDNF(Brain-derived neurotrophic factor;脳由来神経栄養因子)濃度をELISAにより測定した。SIRT1МSC(S)はМSC(М)と比較して、BDNFが高発現であることがわかった(図7)。SIRT1МSCにおけるBDNF濃度は、МSCに対して24時間培養後で4.45倍、48時間培養後で6.30倍及び72時間培養後で7.81倍であった。また、BDNF遺伝子の発現をqRT-PCRにて定量したところ、72時間培養後においてSIRT1МSCにおけるBDNFの発現は、МSCに対して1.54倍であった。なお、qRT-PCRには配列番号5及び6のプライマーセットを用いた。
脂肪由来間葉系幹細胞(Promocell社)を、15,000cells/cm2で培養容器に播種した。24~48時間後、細胞が70-90%のコンフルエント状態であることを確認し、試験1と同様に、SIRT1のmRNAをトランスフェクションした。また、試験2と同様に検討を行い、脂肪由来間葉系幹細胞にSIRT1が発現していることを確認した。
THP1を30,000cells/cm2で12ウェルプレートに播種して、200nMのPMAを添加し、4日間培養した。脂肪由来間葉系幹細胞(以下「ADМSC」という)及びSIRT1のmRNAをトランスフェクションした脂肪由来間葉系幹細胞(以下「SIRT1ADМSC」という)は共培養の前日に0.4μmトランズウェルインサート上に40,000cells/cm2で播種して培養した。共培養開始時に、THP1及びADМSCのウェルに1μg/mLのLPSを添加しLPS刺激を行い、ADМSCを播種したトランズウェルを、THP1を播種したウェル上に設置し、2日間共培養した(37℃,2%CO2)。その後、THP1細胞溶解物を回収し、CD206遺伝子の発現をqRT-PCRにて定量した。その際に配列番号7及び8のプライマーセットを用いた。
臍帯由来間葉系幹細胞(МSC、Promocell社)、試験1と同様にSIRT1のmRNAをトランスフェクションした臍帯由来間葉系幹細胞(SIRT1МSC、Promocell社)、ヒト非小細胞肺癌細胞(A549、American Type Culture Collectionより分譲)、ヒト胎児肺由来正常線維芽細胞(MRC-5、American Type Culture Collectionより分譲)及びヒト小気道上皮細胞(SAEC、ロンザ社)の各細胞を80%コンフルエントになるまで培養して各細胞のtotalRNAを回収し、SIRT1のmRNA発現を定量PCRで確認した。なお、МSC及びSIRT1МSCはGM2培地(Promocell社)、A549及びMRC-5は10%FBSを含むDMEM培地、SAECはロンザ社の推奨培地を用いて、各細胞の推奨播種密度で播種して培養した。また、定量PCRには試験1に記載の配列番号1及び2のプライマーセットを用いた。МSCのSIRT1のmRNA発現量を1とした場合の各細胞のSIRT1のmRNA発現量を表1に示した。
無血清培地(ロート社製)にて培養した臍帯由来間葉系幹細胞(Promocell社)を2.5×105cells分取し、懸濁液の状態でエレクトロポレーション法によりSIRT1mRNAをトランスフェクション(サーモフィッシャー社製)した。その後、6well plateに播種し、37℃で24~72時間培養した後でSIRT1遺伝子発現を確認した。SIRT1遺伝子発現は、配列番号1及び2のプライマーセットを用いてPCRによって確認した。結果を図9(24時間培養後)及び10(72時間培養後)に示す。なお、図中、Ctrlは、エレクトロポレーション無しのコントロール(mRNA無し)、Eはエレクトロポレーションありのコントロール(mRNA無し)、EGFPはエレクトロポレーション法でGFP mRNAを導入したサンプル、SIRT1はエレクトロポレーション法でSIRT1 mRNAを導入したサンプルを示している。
Claims (5)
- SIRT1を高発現することを特徴とする、間葉系幹細胞。
- BDNFを高発現することを特徴とする、間葉系幹細胞。
- 臍帯組織由来である、請求項1又は2に記載の間葉系幹細胞。
- 請求項1から3のいずれか1項に記載の間葉系幹細胞を含有する抗炎症剤。
- 請求項1から3のいずれか1項に記載の間葉系幹細胞を含有する神経疾患治療剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022575594A JPWO2022153996A1 (ja) | 2021-01-14 | 2022-01-12 | |
CN202280009998.4A CN116745407A (zh) | 2021-01-14 | 2022-01-12 | 间充质干细胞、抗炎症剂及神经疾病治疗剂 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-004115 | 2021-01-14 | ||
JP2021004115 | 2021-01-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022153996A1 true WO2022153996A1 (ja) | 2022-07-21 |
Family
ID=82446722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/000658 WO2022153996A1 (ja) | 2021-01-14 | 2022-01-12 | 間葉系幹細胞、抗炎症剤及び神経疾患治療剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2022153996A1 (ja) |
CN (1) | CN116745407A (ja) |
WO (1) | WO2022153996A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180171355A1 (en) * | 2016-12-15 | 2018-06-21 | Synploid Biotek, Llc | Methods of cell renewal |
WO2019093481A1 (ja) * | 2017-11-09 | 2019-05-16 | 北海道公立大学法人札幌医科大学 | 組織再生用医薬及びその製造方法 |
EP3754025A1 (en) * | 2018-01-24 | 2020-12-23 | Slbigen Inc. | Mesenchymal stem cells expressing brain-derived neurotrophic factor and use thereof |
-
2022
- 2022-01-12 CN CN202280009998.4A patent/CN116745407A/zh active Pending
- 2022-01-12 JP JP2022575594A patent/JPWO2022153996A1/ja active Pending
- 2022-01-12 WO PCT/JP2022/000658 patent/WO2022153996A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180171355A1 (en) * | 2016-12-15 | 2018-06-21 | Synploid Biotek, Llc | Methods of cell renewal |
WO2019093481A1 (ja) * | 2017-11-09 | 2019-05-16 | 北海道公立大学法人札幌医科大学 | 組織再生用医薬及びその製造方法 |
EP3754025A1 (en) * | 2018-01-24 | 2020-12-23 | Slbigen Inc. | Mesenchymal stem cells expressing brain-derived neurotrophic factor and use thereof |
Non-Patent Citations (4)
Title |
---|
FU YUE, WANG YAN, DU LIQING, XU CHANG, CAO JIA, FAN TIQIANG, LIU JIANXIANG, SU XU, FAN SAIJUN, LIU QIANG, FAN FEIYUE: "Resveratrol Inhibits Ionising Irradiation-Induced Inflammation in MSCs by Activating SIRT1 and Limiting NLRP-3 Inflammasome Activation", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 14, no. 7, pages 14105 - 14118, XP055952032, DOI: 10.3390/ijms140714105 * |
GUO YANHONG, WANG LIUWEI, GOU RONG, WANG YULIN, SHI XIUJIE, PANG XINXIN, TANG LIN: "SIRT1-modified human umbilical cord mesenchymal stem cells ameliorate experimental peritoneal fibrosis by inhibiting the TGF-β/Smad3 pathway", STEM CELL RESEARCH & THERAPY, vol. 11, no. 1, 18 August 2020 (2020-08-18), XP055952029, DOI: 10.1186/s13287-020-01878-2 * |
HUA WANG, HU ZIXUAN, WU JUN, MEI YUKUN, ZHANG QIAN, ZHANG HENGWEI, MIAO DENGSHUN, SUN WEN: "Sirt1 Promotes Osteogenic Differentiation and Increases Alveolar Bone Mass via Bmi1 Activation in Mice", JOURNAL OF BONE AND MINERAL RESEARCH, vol. 34, no. 6, 28 June 2019 (2019-06-28), Blackwell Science, Inc., US, pages 1169 - 1181, XP055679423, ISSN: 0884-0431, DOI: 10.1002/jbmr.3677 * |
WANG XINXIN; MA SHANSHAN; YANG BO; HUANG TUANJIE; MENG NAN; XU LING; XING QU; ZHANG YANTING; ZHANG KUN; LI QINGHUA; ZHANG TAO; WU : "Resveratrol promotes hUC-MSCs engraftment and neural repair in a mouse model of Alzheimer’s disease", BEHAVIOURAL BRAIN RESEARCH, vol. 339, 2 November 2017 (2017-11-02), ELSEVIER, AMSTERDAM., NL, pages 297 - 304, XP085300681, ISSN: 0166-4328, DOI: 10.1016/j.bbr.2017.10.032 * |
Also Published As
Publication number | Publication date |
---|---|
CN116745407A (zh) | 2023-09-12 |
JPWO2022153996A1 (ja) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6255112B1 (en) | Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells | |
Zhang et al. | Effects of transplanted bone marrow mesenchymal stem cells on the irradiated intestine of mice | |
US20120107413A1 (en) | Pre-natal mesenchymal stem cells | |
JP7048977B2 (ja) | コロニー形成培地及びその使用 | |
US11998617B2 (en) | Gene and cell therapy using cell fusion technology | |
Pavlova et al. | In vitro neuronal induction of adipose-derived stem cells and their fate after transplantation into injured mouse brain | |
US20220204924A1 (en) | Engineered endothelial cells expressing an ets transcription factor | |
US10947500B2 (en) | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same | |
Hoseini et al. | Fibroblast growth factor 1-transfected adipose-derived mesenchymal stem cells promote angiogenic proliferation | |
JPWO2007010858A1 (ja) | 骨格筋組織由来の単一細胞よりクローン化した多能性幹細胞 | |
JP2019528057A (ja) | インビボで血管形成能を有する中胚葉細胞および/または血管内皮コロニー形成細胞様細胞を作製する方法 | |
WO2020045547A1 (ja) | 線維芽細胞の製造方法及びg-csf陽性線維芽細胞集団 | |
JP2018522576A (ja) | 向上された臍帯由来付着型幹細胞、その製造方法及びその用途 | |
CN110121555B (zh) | 包含工程化内皮细胞的血脑屏障 | |
WO2018124292A1 (ja) | 骨格筋細胞及びその誘導方法 | |
US20230374462A1 (en) | Method for producing myocardial stem/progenitor cell and method for suppressing myocardial fibrosis | |
WO2022153996A1 (ja) | 間葉系幹細胞、抗炎症剤及び神経疾患治療剤 | |
JP2019511238A (ja) | 遺伝子送達の増強方法 | |
Xue et al. | The study of the intercellular trafficking of the fusion proteins of herpes simplex virus protein VP22 | |
KR102100490B1 (ko) | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 | |
KR102285613B1 (ko) | 세포융합 기술을 이용한 유전자 및 세포 치료제 및 이의 용도 | |
US20190224243A1 (en) | Enhancement of the Beneficial Effects of Mesenchymal Stem Cell Treatment by the Caveolin-1 Scaffolding Domain Peptide and Subdomains | |
RU2800644C2 (ru) | Способ получения фибробластов и г-ксф-положительная фибробластная масса | |
Xing et al. | Overexpression of CCR2 in mesenchymal stem cells contributes to homing and liver regeneration. | |
KR20200047096A (ko) | 역분화 만능 유도세포 유도용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22739402 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022575594 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280009998.4 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22739402 Country of ref document: EP Kind code of ref document: A1 |